Latest News

06/21/2010

“Ferring Pharmaceuticals Announces Immediate Availability Of Lysteda™, The First Non-Hormonal Therapy Indicated Specifically For Cyclic Heavy Menstrual Bleeding ”

Information for Patients and Physicians Available at www.lysteda.com Parsippany, NJ – June 21...

05/19/2010

“CLINICAL DATA DEMONSTRATES THAT LYSTEDA™ SIGNIFICANTLY REDUCED MENSTRUAL BLOOD LOSS AND LIMITATIONS ON SOCIAL, LEISURE AND PHYSICAL ACTIVITIES IN WOMEN WITH CYCLIC HMB”

Ferring presents findings at The American College of Obstetricians and Gynecologists 58th Annual Cli...

05/10/2010

“FERRING ACQUIRES LYSTEDA™ FROM XANODYNE PHARMACEUTICALS, INC.”

Global Acquisition Expands Ferring’s Role in Women’s Health SAINT-PREX, Switzerland &nd...

04/01/2010

“XANODYNE AND FERRING ANNOUNCE CO-PROMOTE FOR ZIPSOR™”

NEWPORT, Ky. and PARSIPPANY, N.J., April 1 /PRNewswire/ – Xanodyne Pharmaceuticals, Inc., an i...

03/08/2010

“NEW ARTICLE REVEALS TREND TOWARD GREATER USE OF HUMAN MENOPAUSAL GONADOTROPIN IN IN VITRO FERTILIZATION ”

Review Article of hMG Published in US Obstetrics & Gynecology PARSIPPANY, NJ – March 8, 2...

Careers Apply I am ferring.. Are you? Search our career opportunities and find out.

The Ferring USA Product Line


This site contains material about Ferring Pharmaceuticals Inc. (hereinafter "Ferring") and its various products that may be of interest to Ferring's employees and customers, as well as to members of the health care community and the general public. Please feel free to browse this web site. Your access and use of the information contained herein is subject to the following terms and conditions and all applicable laws. By accessing and browsing this web site, you accept, without limitation or qualification, these terms and conditions and acknowledge that they supersede any other agreement between you and Ferring.

Non-US visitors, please visit our international site at www.ferring.com.

©2008-2010 Ferring Pharmaceuticals